Table SI.Primers used to amplify the indicated genes.

Gene	Reverse transcription-qu	antitative PCR primers
Conc	Forward Sequence $(5' - 3')$	Reverse sequence $(5' - 3')$
TPR	AACGCCAGCGTGAGGAATATG	ATTACGTGGTTACCCCTTGCT
GAPDH	ACAGTCAGCCGCATCTTCTT	GACAAGCTTCCCGTTCTCAG

Antibody target	Vendor	Cat.no.
TPR	Abcam	ab170940
phospho-AKT (S473)	CST	4060
AKT	CST	9272
GAPDH	CST	2118
Goat anti-rabbit IgG	Bioworld Technology, Inc.	bs13278

Table SII. Antibodies used in western blotting

Characteristics	Low expression of TPR	High expression of TPR	P-value
n	187	187	
T stage, n (%)			0.813
T1	92 (24.8%)	91 (24.5%)	
T2	49 (13.2%)	46 (12.4%)	
T3	36 (9.7%)	44 (11.9%)	
T4	7 (1.9%)	6 (1.6%)	
N stage, n (%)			0.624
N0	121 (46.9%)	133 (51.6%)	
N1	1 (0.4%)	3 (1.2%)	
M stage, n (%)			0.365
M0	131 (48.2%)	137 (50.4%)	
M1	3 (1.1%)	1 (0.4%)	
Pathologic stage, n (%)			0.294
Stage I	87 (24.9%)	86 (24.6%)	
Stage II	47 (13.4%)	40 (11.4%)	
Stage III	37 (10.6%)	48 (13.7%)	
Stage IV	4 (1.1%)	1 (0.3%)	
Tumor status, n (%)			0.226
Tumor free	108 (30.4%)	94 (26.5%)	
With tumor	71 (20%)	82 (23.1%)	
Sex, n (%)			0.269
Female	55 (14.7%)	66 (17.6%)	
Male	132 (35.3%)	121 (32.4%)	
Race, n (%)			0.815
Asian	76 (21%)	84 (23.2%)	
Black or African American	8 (2.2%)	9 (2.5%)	
White	94 (26%)	91 (25.1%)	
Residual tumor, n (%)			0.086
R0	168 (48.7%)	159 (46.1%)	
R1	5 (1.4%)	12 (3.5%)	
R2	1 (0.3%)	0 (0%)	
Histologic grade, n (%)			0.046

Table SIII. Association	between the expression	of TPR and the clinico	pathological characteristic	s of patients

G135 (9.5%)20 (5.4%)G293 (25.2%)85 (23%)G352 (14.1%)72 (19.5%)G45 (1.4%)7 (1.9%)Adjacent hepatic tissue inflammation, n (%)0.200None67 (28.3%)51 (21.5%)Mild48 (20.3%)53 (22.4%)Severe12 (5.1%)6 (2.5%)Child-Pugh grade, n (%)122 (50.6%)97 (40.2%)B8 (3.3%)13 (5.4%)
G352 (14.1%)72 (19.5%)G45 (1.4%)7 (1.9%)Adjacent hepatic tissue inflammation, n (%)0.200None67 (28.3%)51 (21.5%)Mild48 (20.3%)53 (22.4%)Severe12 (5.1%)6 (2.5%)Child-Pugh grade, n (%)0.168A122 (50.6%)97 (40.2%)
G45 (1.4%)7 (1.9%)Adjacent hepatic tissue inflammation, n (%)0.200None67 (28.3%)51 (21.5%)Mild48 (20.3%)53 (22.4%)Severe12 (5.1%)6 (2.5%)Child-Pugh grade, n (%)0.168A122 (50.6%)97 (40.2%)
Adjacent hepatic tissue inflammation, n (%) 0.200 None 67 (28.3%) 51 (21.5%) Mild 48 (20.3%) 53 (22.4%) Severe 12 (5.1%) 6 (2.5%) Child-Pugh grade, n (%) 0.168 A 122 (50.6%) 97 (40.2%)
None 67 (28.3%) 51 (21.5%) Mild 48 (20.3%) 53 (22.4%) Severe 12 (5.1%) 6 (2.5%) Child-Pugh grade, n (%) 0.168 A 122 (50.6%) 97 (40.2%)
Mild 48 (20.3%) 53 (22.4%) Severe 12 (5.1%) 6 (2.5%) Child-Pugh grade, n (%) 0.168 A 122 (50.6%) 97 (40.2%)
Severe 12 (5.1%) 6 (2.5%) Child-Pugh grade, n (%) 0.168 A 122 (50.6%) 97 (40.2%)
Child-Pugh grade, n (%) 0.168 A 122 (50.6%) 97 (40.2%)
A 122 (50.6%) 97 (40.2%)
B 8 (3.3%) 13 (5.4%)
C 1 (0.4%) 0 (0%)
Fibrosis ishak score, n (%)0.540
0 45 (20.9%) 30 (14%)
1/2 19 (8.8%) 12 (5.6%)
3/4 14 (6.5%) 14 (6.5%)
5/6 41 (19.1%) 40 (18.6%)
Vascular invasion, n (%) 0.285
No 111 (34.9%) 97 (30.5%)
Yes 51 (16%) 59 (18.6%)
Age, median (IQR)63 (53.25, 69)59 (51, 68)0.042
Height, median (IQR)168 (162, 174.75)166 (160, 172)0.039
Weight, median (IQR)72 (62, 84)68 (57, 79)0.034
BMI, median (IQR)24.88 (22.38, 28.67)24.3 (21.21, 28.65)0.260
AFP (ng/ml), median (IQR) 11 (4, 112) 24 (4.5, 820) 0.054
Albumin(g/dl), median (IQR)4 (3.5, 4.3)4 (3.5, 4.4)0.076
Prothrombin time, median (IQR) 1.1 (1, 9.1) 1.1 (1, 9.38) 0.603

Categorical variables are expressed as frequencies and percentages. Continuous variables, including parametric and nonparametric variables, are indicated as the mean \pm standard deviation (SD) and median with interquartile range, respectively. TPR, translocated promoter region.